ATLASATLAS fair value
ATLAS has no fair value for this stock today.
LENSAR (LNSR)
LENSAR stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$5.92▼ -0.67%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on LENSAR in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On LENSAR
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives LENSAR a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $5.40 and $6.43; in 9 out of 10, between $4.63 and $7.49. Estimated annual volatility is 46%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $82.9M
- P/E ratio
- 5.6
- 52-week high
- $12.94
- 52-week low
- $4.95
- Revenue (12 months)
- $60.3M
- Revenue growth (YoY)
- +9.2%
- Gross margin
- 46.4%
- Operating margin
- -42.1%
- Net margin
- -58.7%
- Return on equity
- 357.3%
- Free cash flow (12 months)
- $-24.4M
- Beta
- 0.97
What this means
ATLAS does not publish a fair value for LNSR right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks LNSR has traded between $4.95 and $12.94. Today it is 54.3% below that high and 20% above its low.
On the business: revenue grew 9.2% year over year; net margin is 58.7%; it trades at 5.6 times earnings.
Its beta is 0.97: it moves roughly in line with the market.
About the company
LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management.
Want to see everything about LENSAR?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does LENSAR do?
LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management.
What is the chance LNSR goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, LNSR ends the month between $5.40 and $6.43.
How big is LENSAR and what is its P/E ratio?
LENSAR's market capitalization is $82.9M. Its price-to-earnings (P/E) ratio is 5.6: you pay $5.6 for each $1 of yearly earnings.
How volatile is LNSR?
ATLAS estimates annual volatility at 46%. In a typical month, half of the outcomes end between $5.40 and $6.43.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer